Scott L Burrows
Chief Financial Officer · 3 filings · Latest: May 1, 2026
Spyre Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
SYRE | Scott L Burrows | Chief Financial Officer | May 1, 2026 | Sale | $71.37 | 12,500 | $892.1K | 97,994 | |
SYRE | Scott L Burrows | Chief Financial Officer | May 1, 2026 | Option Exercise | $14.50 | 12,500 | $181.3K | 110,494 | |
SYRE | SCOTT BURROWS | — | May 1, 2026 | Proposed Sale | $74.45 | 27,500 | $2.0M | — | |
SYRE | Scott L Burrows | Chief Financial Officer | Apr 1, 2026 | Sale | $49.34 | 7,500 | $370.1K | 97,994 | |
SYRE | Scott L Burrows | Chief Financial Officer | Apr 1, 2026 | Option Exercise | $14.50 | 7,500 | $108.8K | 105,494 | |
SYRE | Scott L Burrows | Chief Financial Officer | Mar 3, 2026 | Sale | $40.65 | 2,500 | $101.6K | 97,994 | |
SYRE | Scott L Burrows | Chief Financial Officer | Mar 3, 2026 | Option Exercise | $14.50 | 2,500 | $36.3K | 100,494 | |
SYRE | SCOTT BURROWS | — | Mar 3, 2026 | Proposed Sale | $42.49 | 10,000 | $424.9K | — |